Caldan Therapeutics Raises £4.45M in Series A Funding

Caldan Therapeutics, a Glasgow-based diabetes startup, has raised £4.45 million in Series A funding led by Epidarex Capital, with participation from the Scottish Investment Bank. The company develops novel therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications.

Caldan Therapeutics Secures £4.45 Million Series A Funding for Diabetes Therapeutics

Caldan Therapeutics Ltd, a Glasgow, UK-based diabetes startup, develops novel therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications. The company, which has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow, aims to address the market need for T2D treatments that address all aspects of the disease, including insulin resistance, pancreatic islet cell failure, inappropriate insulin secretion, and inflammation in muscle, liver and adipose tissue.

A Glasgow, UK-based diabetes startup developing novel therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications.

10 years ago

Caldan Therapeutics Secures £4.45 Million Series A Funding for Diabetes Therapeutics

ProblemHealthcare

Solution

Covered on